Impact of CD3 expression on outcome in pediatric anaplastic large cell lymphoma

• DOI: 10.3389/fonc.2025.1569370
• Publication Date: 2025-05-15T05:29:10Z
• Authors: Ahmed Salah; Hanafy Hafez; Samah Semary; Eman Nageb; Sonia Soliman; Iman Zaky; Shahenda M. Shahin; Leslie Lehmann; Alaa ElHaddad
• Keywords: Brentuximab vedotin; Anaplastic large-cell lymphoma

Background Anaplastic large cell lymphoma (ALCL) constitutes 10-15% of childhood non-Hodgkin lymphoma. EFS is 70% and currently 80% with the additional targeted agents such as CD30 directed conjugated monoclonal antibody brentuximab or ALK inhibitors crizotinib. Expression CD3, a T-cell marker, can be lost diminished in some ALCL cases. The literature conflicting on whether CD3 expression affects prognosis, it has been analyzed mostly relapse setting. purpose this study was to determine effect survival its relation other prognostic variables newly diagnosed patients pediatric treated at single oncology center. Methods A retrospective done 89 (under 18 years old) Children’s Cancer Hospital Egypt (CCHE-57357) from July 2007 December 2019. Immunohistochemistry utilized confirm diagnosis tumor cells. impact event-free (EFS), relapse-free (RFS) overall (OS)) analyzed. Results median age 10.7 male female ratio 1.8:1. majority (85.4%) were positive. positive 31 (34.8%) patients. follow-up period 60 months. five-year OS, EFS, RFS rates for entire group 84.3%, 73.1%, 81.5%, respectively. positivity associated higher incidence CNS involvement (p=0.03) but did not significantly patient outcomes (EFS, OS). However, stage, B symptoms, skin linked shorter survival. Conclusion This indicates that may major factor predicting ALCL. Additional research needed understand association disease.